Therefore, the aim of the present study was to investigate the expression of CLDN18.2 in CCA with the VENTANA® CLDN18 (43‐14A) antibody, which was used in the SPOTLIGHT study, to determine whether a subset of CCA patients could potentially benefit from anti‐CLDN18.2 antibody therapy. Here, CLDN18 is linked to cholangiocarcinoma.